CLASS II ONGOING Drug recall · Reported 25 Mar 2026 · FDA Enforcement Report

Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution 0.2%/0.5%* recalled

Apotex is recalling Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution 0.2%/0.5%*, distributed nationwide in the US. The recall was initiated on 5 Mar 2026 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLots VJ8599, Exp Date 09/30/2026 & VL1668, Exp Date 01/31/2027
NDC60505-0589
Quantity recalled107,136 vials

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0407-2026
FDA event ID
98536
Recalling firm
Apotex, Weston, FL
Manufacturer
Apotex Corp.
Classification
Class II
Status
Ongoing
Recall initiated
5 Mar 2026
FDA classified
27 Mar 2026
Reported
25 Mar 2026
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Sterility
Drug class
Eye Drops

Timeline

5 Mar 2026Recall initiated by company
25 Mar 2026Published in enforcement report+20 days
27 Mar 2026Classified by FDA+2 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Lack of Assurance of Sterility

A sterility recall means a product that must be sterile, such as an injection or eye drop, may be contaminated. Using a non-sterile product can cause serious infection.

Product as listed by the FDA

Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution 0.2%/0.5%*, 5 mL, Rx Only, Sterile, Apotex Corp. Manufactured for: Apotex Corp., Weston, FL 33326, NDC 60505-0589-1.

Where it was distributed

U.S. Nationwide

Nationwide

Questions about this recall

Why was it recalled?

Lack of Assurance of Sterility

Which lots are affected?

Lots VJ8599, Exp Date 09/30/2026 & VL1668, Exp Date 01/31/2027

Where was it sold?

U.S. Nationwide

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Apotex

All 75
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIPaxil CR, Paroxetine, Extended-Release Tablets, 37.5mg recalledApotexPotency & AssayNationwide
DrugCLASS IIDesmopressin Nasal Spray, USP, 10 mcg/ bottle (50 doses) recalledApotexOtherNationwide
DrugCLASS IIKetorolac Tromethamine Ophthalmic Solution recalled by ApotexKetorolac TromethamineApotexSterilityNationwide
DrugCLASS IIBrimonidine Tartrate/Timolol Maleate Ophthalmic Solution recalledBrimonidine Tartrate/timolol Maleate Ophthalmic SolutionApotexSterilityNationwide
DrugCLASS IIBrimonidine Tartrate/Timolol Maleate Ophthalmic Solution, 0.2%/0.5% recalledBrimonidine Tartrate/timolol Maleate Ophthalmic SolutionApotexSterilityNationwide

Other Brimonidine recalls

All 9
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIBrimonidine Tartrate/Timolol Maleate Ophthalmic Solution recalledBrimonidine Tartrate/timolol Maleate Ophthalmic SolutionApotexSterilityNationwide
DrugCLASS IIBrimonidine Tartrate/Timolol Maleate Ophthalmic Solution, 0.2%/0.5% recalledBrimonidine Tartrate/timolol Maleate Ophthalmic SolutionApotexSterilityNationwide
DrugCLASS IIBrimonidine Tartrate Ophthalmic Solution recalled by ApotexBrimonidine TartrateApotexSterilityNationwide
DrugCLASS IIIBrimonidine Tartrate Opthalmic Solution recalledBrimonidine TartrateSomerset TherapeuticsPotency & AssayNationwide
DrugCLASS IIIBrimonidine Tartrate Opthalmic Solution recalledBrimonidine TartrateSomerset TherapeuticsPotency & AssayNationwide